Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma
Authors:
Open Access
- 1 February 2005
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 16 (2) , 279-281
Abstract
Objectives: The prognosis for patients with unresectable biliary tract cancer is poor and existing chemotherapy is relatively ineffective. Therefore, a need exists for new, effective chemotherapeutic regimens. The aim of this study was to determine the efficacy and safety profile of gemcitabine plus cisplatin in patients with unresectable biliary tract cancer (cholangiocarcinoma) and gall bladder cancer. Methods: From December 2000 to July 2002, 43 patients received gemcitabine 1250 mg/m2 in a 30-min i.v. infusion on d1, 8 and cisplatin 75 mg/m2 in a 2-h i.v. infusion on d1 (with appropriate hydration), every 3 weeks. Eligibility: Normal hematologic parameters and creatinine levels; serum bilirubin Results: Forty-three patients enrolled; 40 were assessable (three patients were not assessable due to incomplete treatment; they chose to discontinue chemotherapy after the first cycle). There were 23 males and 17 females, median age 50 years (range 31–69), median Karnofsky PS 80%. Tumor types: cholangiocarcinoma (39), gall bladder cancer (1). Median number of chemotherapy courses was four (range 1–8). Overall response rate was 27.5% (PR in 11 pts), with 32.5% SD and/or minor response. Median survival time was 36 weeks. Grade 3 hematologic toxicity: anemia (4.33%), leukopenia (1.73%). Non-hematologic toxicity (i.e. rash, nausea, vomiting, neuropathy and myalgia) ranged from mild to moderate. Conclusions: Gemcitabine plus cisplatin is active in biliary tract carcinoma. These data warrant further investigation of single-agent gemcitabine versus gemcitabine plus cisplatin or its derivative, i.e. oxaliplatin.Keywords
This publication has 13 references indexed in Scilit:
- Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experienceAnnals of Oncology, 2004
- Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II studyAnnals of Oncology, 2003
- Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract CancerAmerican Journal of Clinical Oncology, 2003
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Treatment of Inoperable and/or Metastatic Biliary Tree Carcinomas With Single-Agent Gemcitabine or in Combination With Levofolinic Acid and Infusional Fluorouracil: Results of a Multicenter Phase II StudyJournal of Clinical Oncology, 2001
- Chemotherapy with gemcitabine in patients with advanced gallbladder carcinomaZeitschrift für Gastroenterologie, 2000
- Effects of 5-Fluorouracil and Leucovorin in the Treatment of Pancreatic–Biliary Tract AdenocarcinomasAmerican Journal of Clinical Oncology, 2000
- Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatinAnnals of Oncology, 1998
- Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancerAnnals of Oncology, 1996